Implementing a Program of Talimogene laherparepvec

Implementing a Program of Talimogene laherparepvec Ann Surg Oncol (2018) 25:1828–1835 https://doi.org/10.1245/s10434-018-6361-5 O R I G IN AL ARTI CL E – MELA NO MA S 1 2 3 4 Frances Collichio, MD , Lauren Burke, MD , Amber Proctor, Pharm D , Diana Wallack, BS , 5 6 6 Anthony Collichio, BSc , Patricia K. Long, MSN, FNP-C , and David W. Ollila, MD Division of Hematology-Oncology, Department of Medicine, The University of North Carolina, Chapel Hill, NC; 2 3 Department of Radiology, The University of North Carolina, Chapel Hill, NC; Department of Pharmacy, The University 4 5 of North Carolina, Chapel Hill, NC; The Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Boston University, Boston, MA; Division of Surgical Oncology, The University of North Carolina, Chapel Hill, NC ABSTRACT quality of treatment for patients who suffer from advanced Background. Oncolytic viruses are genetically engineered melanoma. or naturally occurring viruses that selectively replicate in cancer cells without harming normal cells. Talimogene laherparepvec (Imlygic ), the first oncolytic viral therapy BACKGROUND approved for treatment of cancer, was approved for treat- ment of locally advanced melanoma in October 2015. Oncolytic viruses are designed to replicate uncontrol- Purpose. As a biologic product, use of T. laherparepvec in lably http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Loading next page...
 
/lp/springer_journal/implementing-a-program-of-talimogene-laherparepvec-Ixc3UxgyvJ
Publisher
Springer Journals
Copyright
Copyright © 2018 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery
ISSN
1068-9265
eISSN
1534-4681
D.O.I.
10.1245/s10434-018-6361-5
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2018) 25:1828–1835 https://doi.org/10.1245/s10434-018-6361-5 O R I G IN AL ARTI CL E – MELA NO MA S 1 2 3 4 Frances Collichio, MD , Lauren Burke, MD , Amber Proctor, Pharm D , Diana Wallack, BS , 5 6 6 Anthony Collichio, BSc , Patricia K. Long, MSN, FNP-C , and David W. Ollila, MD Division of Hematology-Oncology, Department of Medicine, The University of North Carolina, Chapel Hill, NC; 2 3 Department of Radiology, The University of North Carolina, Chapel Hill, NC; Department of Pharmacy, The University 4 5 of North Carolina, Chapel Hill, NC; The Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Boston University, Boston, MA; Division of Surgical Oncology, The University of North Carolina, Chapel Hill, NC ABSTRACT quality of treatment for patients who suffer from advanced Background. Oncolytic viruses are genetically engineered melanoma. or naturally occurring viruses that selectively replicate in cancer cells without harming normal cells. Talimogene laherparepvec (Imlygic ), the first oncolytic viral therapy BACKGROUND approved for treatment of cancer, was approved for treat- ment of locally advanced melanoma in October 2015. Oncolytic viruses are designed to replicate uncontrol- Purpose. As a biologic product, use of T. laherparepvec in lably

Journal

Annals of Surgical OncologySpringer Journals

Published: Feb 7, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off